Clinical Trial Detail

NCT ID NCT01430351
Title Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

glioblastoma multiforme

gliosarcoma

Therapies

Metformin + Temozolomide

Mefloquine + Temozolomide

Memantine + Metformin + Temozolomide

Mefloquine + Memantine + Temozolomide

Mefloquine + Memantine + Metformin + Temozolomide

Temozolomide

Mefloquine + Metformin + Temozolomide

Memantine + Temozolomide

Age Groups: adult senior

No variant requirements are available.